{"id":"NCT00907777","sponsor":"GlaxoSmithKline","briefTitle":"Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™","officialTitle":"Vaccination With the Pneumococcal Vaccine GSK 1024850A or Prevenar™ at Approximately 4 Years of Age in Children Primed With 3 Doses of GSK 1024850A Vaccine or Prevenar™ and Boosted With 23-valent Pneumococcal Plain Polysaccharide Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06-23","primaryCompletion":"2009-10-05","completion":"2009-10-05","firstPosted":"2009-05-25","resultsPosted":"2017-01-06","lastUpdate":"2020-11-23"},"enrollment":52,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal","Streptococcus Pneumoniae"],"interventions":[{"type":"BIOLOGICAL","name":"Pneumococcal conjugate vaccine GSK 1024850A","otherNames":[]},{"type":"BIOLOGICAL","name":"Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)","otherNames":[]}],"arms":[{"label":"Pn Group","type":"EXPERIMENTAL"},{"label":"Prev Group","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this study is to assess the immune response, safety and reactogenicity following administration of an additional dose of a pneumococcal conjugate vaccine at approximately 4 years of age in children previously vaccinated with 3 primary doses of GSK 1024850A or Prevenar™ vaccine within the first 6 months of life and a booster dose of plain polysaccharide pneumococcal (Pneumovax 23™) vaccine at 11-14 months of age.\n\nAntibody persistence will also be assessed at approximately 4 years of age in children previously vaccinated with 3 doses of either GSK 1024850A or Prevenar™ vaccine followed by a booster dose of Pneumovax 23™.\n\nThis protocol posting deals with objectives \\& outcome measures of the extension phase at year 4. The objectives \\& outcome measures of the primary phase are presented in a separate protocol posting (NCT 00307541). The objectives \\& outcome measures of the booster phase are presented in a separate protocol posting (NCT 00333450).","primaryOutcome":{"measure":"Vaccine Pneumococcal Serotype Antibody Concentrations","timeFrame":"Before (PRE) and one month after (POST) the additional dose","effectByArm":[{"arm":"Prevnar Group","deltaMin":0.14,"sd":null},{"arm":"GSK 1024850A Group","deltaMin":0.38,"sd":null}],"pValues":[]},"eligibility":{"minAge":"46 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":17,"countries":["Germany"]},"refs":{"pmids":["21909049"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Pain","Redness","Swelling","Drowsiness","Loss of appetite"]}}